Entrada Therapeutics Banner Image

Entrada Therapeutics

  • Ticker TRDA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Entrada Therapeutics Logo Image
  • 51-200 Employees
  • Based in Boston, Massachusetts
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeuticsMore into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. The Company’s lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as their partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1).
3.0 / 5.0 (3)

Entrada Therapeutics reports have an aggregate usefulness score of 3.0 based on 3 reviews.

Entrada Therapeutics

Most Recent Annual Report

Entrada Therapeutics
MOST RECENT 2022 Annual Report
Entrada Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!